NCT03732781View on ClinicalTrials.gov

Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

May 27, 2020

Primary Completion Date

May 14, 2025

Study Completion Date

May 14, 2025

Conditions
Peritoneal CarcinomaColorectal Carcinoma
Interventions
DRUG

Radspherin

"Radspherin® suspension consists of degradable calcium carbonate microparticles with the α-emitting radionuclide 224Ra in suspension.~Radspherin® will be provided in a R10 vial filled with 10 mL suspension of 224Ra adsorbed on 1 g calcium carbonate microparticles. The volume to be administered will contain 0.7-1 g calcium carbonate microparticles with 1-7 MBq 224Ra. 224Ra has a half-life of 3.6 days."

Trial Locations (2)

Unknown

Oslo University Hospital, Oslo

Akademiska, Uppsala

Sponsors

Lead Sponsor

Oncoinvent AS
All Listed Sponsors
lead

Oncoinvent AS

INDUSTRY

NCT03732781 - Study of Radspherin® in Colorectal Carcinoma Subjects With Peritoneal Carcinomatosis Treated With HIPEC | Biotech Hunter | Biotech Hunter